INDEMNIFICATION AGREEMENTIndemnification Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of [ ] (the “Effective Date”) by and between 89bio, Inc., a Delaware corporation (the “Company”), and [ ] (the “Indemnitee”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 17th day of September, 2019, by and among 89bio, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any additional purchaser that becomes a party to this Agreement in accordance with Section 6.9 hereof.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Sublicense Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations • New York
This Sublicense Agreement (the “Agreement”) is made and entered into as of April 16th, 2018, by and between 89Bio, Ltd. a company organized under the laws of Israel (“Company”), and ratiopharm GmbH company a company organized under the laws of Germany (“Teva”). This Sublicense Agreement shall become effective upon the closing of the Asset Purchase Agreement, as defined below, (the “Effective Date”).
EMPLOYMENT AGREEMENT This Agreement constitutes an advance notice to the Employee under the Notice to the Employee Law (Employment Terms), 2002Employment Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations
THIS EMPLOYMENT AGREEMENT (this “Agreement” dated as of April 23, 2018, is made and entered by and between 89bio Ltd., a company organized under the laws of the state of Israel, whose registered address is 89 Medinat HaYehudim St., Herzliya, Israel (the “Company” and Ram Waisbourd (the “Employee”).
ASSET TRANSFER AND LICENSE AGREEMENT - FGF-21Asset Transfer and License Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations
THIS ASSET TRANSFER AND LICENSE AGREEMENT – FGF-21 (this “Agreement”), dated as of the 16th day of April, 2018 (the “Effective Date”), is by and between (a) 89Bio Ltd. (“Company”) on the one hand, and (b) Ratiopharm GmbH, Teva Branded Pharmaceutical Products R&D, Inc. and Teva Pharmaceutical Industries Ltd, (collectively “Teva”) on the other. Company, on the one hand, and Teva, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. REAGENT SUPPLY AND TECHNOLOGY TRANSFER...Reagent Supply and Technology Transfer Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations
WHEREAS, SUPPLIER and BUYER agreed to enter into a supply agreement (“Agreement”) to serve as the general framework for, and to govern the supply of [***], [***] and [***] by SUPPLIER to BUYER or its Affiliates; and
